Lifitegrast Eye Drops

Lifitegrast is an FDA approved drug indicated for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca.

The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.

Lifitegrast Formulation

  • Lifitegrast 5%
  • Disodium Hydrogen Phosphate Dodecahydrate
  • Sodium Chloride
  • Sodium Perborate
  • Sodium Thiosulfate Pentahydrate
  • Sodium Hydroxide
  • WFI

Possible Side Effects

  • Blurred vision (1-5%)
  • Conjunctival hyperemia (1-5%)
  • Eye irritation (1-5%)
  • Headache (1-5%)
  • Increased lacrimation (1-5%)
  • Eye discharge (1-5%)
  • Eye discomfort (1-5%)
  • Eye pruritus (1-5%)
  • Sinusitis (1-5%)


Related Articles

Comments

Popular posts from this blog

Top 10 Pharmaceutical Companies in Bangladesh 2017

Advanced Animal Health in Bangladesh

Rapid Growth : The Focusing Point of Incepta Pharma